UNLABELLED: Iodine-123-labeled iodobenzofuran ([123I]IBF) is a potent dopamine D2 antagonist that provides good visualization of D2 receptors in primates. METHODS: The feasibility of measuring dopamine D2 binding potential with [123I]IBF in humans was evaluated in eight healthy subjects. Following [123I]IBF injection (6 mCi), scans were acquired every 10 min for 160 min with the brain-dedicated CERASPECT camera. Arterial activities were obtained at various intervals and corrected for the presence of metabolites by extraction followed by reverse-phase high-performance liquid chromatography. RESULTS: Reconstructed images exhibited adequate basal ganglia-to-occipital ratios (from 1.96 +/- 0.34 at 30 min to 3.54 +/- 0.71 at 150 min, mean +/- s.d.). Time-activity curves demonstrated reversibility, with peak basal ganglia uptake at 50 +/- 25 min. Regional time-activity curves were analyzed with kinetic three-compartment modeling and graphic analysis. In all subjects, D2 binding potential values, as derived by both methods, were in excellent agreement (mean +/- s.d. D2 binding potential = 129 +/- 51). An empiric count ratio method that does not require measurement of arterial tracer concentrations was evaluated and found to be in reasonable agreement with the model-derived binding potential. CONCLUSION: Iodine-131-IBF is a suitable ligand for quantitative studies of D2 receptor density with SPECT in humans.
UNLABELLED: Iodine-123-labeled iodobenzofuran ([123I]IBF) is a potent dopamine D2 antagonist that provides good visualization of D2 receptors in primates. METHODS: The feasibility of measuring dopamine D2 binding potential with [123I]IBF in humans was evaluated in eight healthy subjects. Following [123I]IBF injection (6 mCi), scans were acquired every 10 min for 160 min with the brain-dedicated CERASPECT camera. Arterial activities were obtained at various intervals and corrected for the presence of metabolites by extraction followed by reverse-phase high-performance liquid chromatography. RESULTS: Reconstructed images exhibited adequate basal ganglia-to-occipital ratios (from 1.96 +/- 0.34 at 30 min to 3.54 +/- 0.71 at 150 min, mean +/- s.d.). Time-activity curves demonstrated reversibility, with peak basal ganglia uptake at 50 +/- 25 min. Regional time-activity curves were analyzed with kinetic three-compartment modeling and graphic analysis. In all subjects, D2 binding potential values, as derived by both methods, were in excellent agreement (mean +/- s.d. D2 binding potential = 129 +/- 51). An empiric count ratio method that does not require measurement of arterial tracer concentrations was evaluated and found to be in reasonable agreement with the model-derived binding potential. CONCLUSION:Iodine-131-IBF is a suitable ligand for quantitative studies of D2 receptor density with SPECT in humans.
Authors: Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle Journal: J Neurosci Date: 2002-05-01 Impact factor: 6.167
Authors: M Reimold; C Solbach; S Noda; J-E Schaefer; M Bartels; M Beneke; H-J Machulla; R Bares; T Glaser; H Wormstall Journal: Psychopharmacology (Berl) Date: 2006-11-17 Impact factor: 4.530
Authors: David Elmenhorst; Philipp T Meyer; Andreas Matusch; Oliver H Winz; Karl Zilles; Andreas Bauer Journal: Eur J Nucl Med Mol Imaging Date: 2007-01-23 Impact factor: 9.236
Authors: A Soricelli; A Postiglione; M R Grivet-Fojaja; P P Mainenti; A Discepolo; A Varrone; M Salvatore; N A Lassen Journal: Eur J Nucl Med Date: 1996-10
Authors: Susanne Nikolaus; Christina Antke; Markus Beu; Konstantin Kley; Andreas Wirrwar; Joseph P Huston; Hans-Wilhelm Müller Journal: Eur J Nucl Med Mol Imaging Date: 2010-11-26 Impact factor: 9.236
Authors: Jeffrey M Miller; Kathleen G Brennan; Todd R Ogden; Maria A Oquendo; Gregory M Sullivan; J John Mann; Ramin V Parsey Journal: Neuropsychopharmacology Date: 2009-05-20 Impact factor: 7.853